Isomorphic Labs banked over €1,880M ($2B+) in a growth round led by Thrive Capital. The financing includes participation from its parent company, Alphabet. The London-based firm represents one of the largest private allocations to a UK-based biotech entity to date.
Founded as a commercial spinout from Google’s DeepMind, Isomorphic Labs focuses on drug discovery through biological modelling. The company uses computational techniques to predict how proteins interact and to identify small molecules that could form the basis of new medicines. Its platform aims to reduce the time and cost associated with traditional laboratory-based drug development.
The company maintains a high-profile presence in the British "Golden Triangle" of life sciences. It previously entered into major strategic collaborations with pharmaceutical giants Eli Lilly and Novartis, deals that carried an aggregate value exceeding €2.8B ($3B) in potential milestones. This new capital injection follows the successful deployment of its AlphaFold technology, which mapped the structures of almost all known proteins.
Large-scale growth rounds in the UK biotech sector reflect a maturing ecosystem where deep-tech breakthroughs in artificial intelligence move rapidly from academic research into clinical-grade commercial pipelines.
Originally reported by Tech Funding News.